PF-04236921 clinical trials
Also written PF-04236921.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses PF-04236921 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 3 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses PF-04236921 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRPCompletedPhase 2Tourmaline Bio, Inc., a Novartis CompanyNCT06362759Written as TOUR006 - 50 MG
- A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye DiseaseActive, not recruitingPhase 2Tourmaline Bio, Inc., a Novartis CompanyNCT06088979Written as TOUR006 - 20 MG
- B0151005 Open-Label Extension StudyCompletedPhase 2PfizerNCT01345318Written as PF-04236921
- Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus ErythematosusCompletedPhase 2PfizerNCT01405196Written as PF-04236921
- A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF TherapyCompletedPhase 2PfizerNCT01287897Written as PF-04236921 SC injection
- Pharmacokinetics And Tolerability Of Subcutaneous Administration Of PF 04236921 In Healthy VolunteersCompletedPhase 1PfizerNCT01166555Written as PF-04236921
Codes
What other systems call PF-04236921 · ClinicalTrials.gg INT000710
- MeSH (NLM) C000620303PF-04236921One source NLM
- UNII (FDA) 2NHW9AKY9CPACIBEKITUGConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000620303 | PF-04236921 | One source NLM |
| UNII (FDA) | 2NHW9AKY9C | PACIBEKITUG | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.